PCN160 Potential Impact of Advanced Therapy Medicinal Products on Irish Hematology-Oncology Care Pathway

Despite recent advances, there remains a need to improve treatment options and survival outcomes for patients with hematological malignancies. Considerable research is ongoing develop advanced therapy medicinal products (ATMPs) in this disease area. Some ATMPs have already received regulatory apprvoal the number of therapeutic range indications approved will probably increase coming years. Research objective estimate Irish malignancies who may benefit from 5-year period, 2021 - 2025. Citeline® database was used identify clinical trials which had potential support product registration or indication expanison Eligible patient numbers were sourced adapted National Cancer Registry Ireland (NCRI) pbulications. Clinical uptake estimates HTA reports, where available. Total estimated hematology could during period evaluated 311. This increases 24 113 Of evaluated, its that largest be multiple myeloma (31% total population) non-Hodgkins lymphoma (29%). The remainder identified acute lymphoblastic leukemia (19%), mantle cell (11%) chronic lymphocytic (4%). steadily over period. provides useful healthcare decision makers can help inform future decisions on resource allocations. Continued investment both health system capacity new medicines funding required ensure an equitable opportunity access global advances healthcare.